SCHEDULE 13G: Laurence W. Lytton Discloses 5.6% Passive Stake in AYTU Biopharma

Laurence W. Lytton has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in AYTU Biopharma, Inc. as of June 9, 2025.

Summary

• Laurence W. Lytton has filed a Schedule 13G, indicating beneficial ownership of 506,605 shares of AYTU Biopharma, Inc. Common Stock.
• This ownership represents 5.6% of the company's outstanding Common Stock, based on 8,976,914 shares outstanding as of June 9, 2025.
• The reported shares include 454,505 shares with sole voting and dispositive power, and 52,100 shares with shared voting and dispositive power.
• In addition to the common stock, Mr. Lytton holds warrants to purchase 2,216,666 shares of Common Stock, subject to a 4.99% beneficial ownership limitation.
• The filing confirms that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by an individual, which can be viewed as a vote of confidence, but it is a routine regulatory disclosure and does not contain operational or financial performance updates.

Positives

• The disclosure of a significant passive stake by an individual investor can be interpreted as a vote of confidence in AYTU Biopharma's long-term prospects.

Risks

• The document explicitly states that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment approach rather than an activist one.

Future Outlook

The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine regulatory disclosure of a significant passive ownership stake and does not provide specific insights into broader industry trends or competitive landscape for AYTU Biopharma.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive investor may provide some level of confidence or stability regarding the company's ownership structure.

Key Dates

Keywords

AYTU Biopharma, Schedule 13G, beneficial ownership, passive investment, Laurence W. Lytton, common stock, SEC filing